Johnson & Johnson's Varipulse device, approved by the FDA for treating atrial fibrillation, combines Carto 3 system and pulsed-field ablation. It enhances ablation accuracy, reduces radiation exposure, and offers high success rates in treating patients based on the admIRE trial results.